Data / Form D filings / ManaT Bio, Inc.
ManaT Bio, Inc.: Form D filing
ManaT Bio, Inc., a biotechnology company in Baltimore, MD, filed a Form D with the SEC in 2023. The latest, on October 25, 2023, reports $72.1 million sold of a $153 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1300 THAMES STREET, SUITE 20, Baltimore, MD, 21231
- Phone
- (301) 615-0491
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1997857
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 25, 2023 | New notice | $152,960,126 | $72,147,626 | $80,812,500 | 9 | Oct 10, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Cary G. Pfeffer | Executive Officer, Director | |
| R. Jacob Vogelstein | Director | |
| Andrea G. Van Elsas | Executive Officer, Director | |
| Raymond Camahort | Director | |
| Jack Nielsen | Director | |
| Andrew Pardoll | Director | |
| ManaT Jacob Holdings, LLC | Promoter |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Oct 23, 2023 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ManaT Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.